Danoprevir - Array BioPharma/Roche

Drug Profile

Danoprevir - Array BioPharma/Roche

Alternative Names: ASC-08; ITMN-191; ITMN-B; R-7227; RG-7227; RO-5190591

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma; InterMune
  • Developer Ascletis; Roche
  • Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 01 May 2017 Ascletis Pharmaceuticals completes a phase III trial for Hepatitis C (Combination therapy; Treatment-naive) in China (NCT03020082)
  • 01 Feb 2017 Ascletis completes the phase II EVEREST trial in Hepatitis C (Combination therapy; Treatment-naive) in Taiwan (NCT03020095)
  • 01 Feb 2017 Ascletis Pharmaceuticals completes a phase II trial for Hepatitis C (Combination therapy; Treatment-naive) in China (NCT03020004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top